Keratoplasty postoperative treatment update

Cornea

Volumn 32, Issue 11 SUPPL, 2013, Pages

  Shimmura Tomita, MacHiko ^a,b   Shimmura, Shigeto ^c   Satake, Yoshiyuki ^b   Shimazaki Den, Seika ^b   Omoto, Masahiro ^b   Tsubota, Kazuo ^c   Shimazaki, Jun ^b,c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOKYO DENTAL COLLEGE   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

atopic dermatitis; cyclosporine; keratoplasty; steroid; tacrolimus

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; FLUOROMETHOLONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTICLE; ATOPIC DERMATITIS; ATOPIC KERATOCONJUNCTIVITIS; BACKACHE; BLEPHARITIS; CLINICAL EFFECTIVENESS; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ECZEMA; FOLLOW UP; GOLD STANDARD; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KERATITIS; KERATOCONJUNCTIVITIS; KERATOCONUS; KERATOMYCOSIS; NAUSEA; PATIENT SAFETY; PENETRATING KERATOPLASTY; POSTKERATOPLASTY ATOPIC SCLEROKERATITIS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; THORAX PAIN; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; DERMATITIS, ATOPIC; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOPLASTY, PENETRATING; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; TACROLIMUS; YOUNG ADULT;

EID: 84885965318     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3182a2c937     Document Type: Article

References (30)

1. Inoue K, Amano S, Oshika T, et al. A 10-year review of penetrating keratoplasty. Jpn J Ophthalmol. 2000;44:139-145. (Pubitemid 30133196)
2. Koay PY, Lee WH, Figueiredo FC. Opinions on risk factors and management of corneal graft rejection in the United Kingdom. Cornea. 2005; 24:292-296. (Pubitemid 40418338)
3. Price FW Jr, Price DA, Ngakeng V, et al. Survey of steroid usage patterns during and after low-risk penetrating keratoplasty. Cornea. 2009;28:865-870.
4. Randleman JB, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns (2004). Cornea. 2006;25:286-290.
5. Shimazaki J, Iseda A, Satake Y, et al. Efficacy and safety of long-term corticosteroid eye drops after penetrating keratoplasty: a prospective, randomized, clinical trial. Ophthalmology. 2012;119:668-673.
6. Merion RM, White DJ, Thiru S, et al. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med. 1984;310:148-154. (Pubitemid 14224108)
7. Modry DL, Oyer PE, Jamieson SW, et al. Cyclosporine in heart and heart-lung transplantation. Can J Surg. 1985;28:274-280, 282.
8. Shiba N, Chan MC, Kwok BW, et al. Analysis of survivors more than 10 years after heart transplantation in the cyclosporine era: Stanford experience. J Heart Lung Transplant. 2004;23:155-164. (Pubitemid 38175292)
9. Birnbaum F, Bohringer D, Sokolovska Y, et al. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation. 2005;79:964-968. (Pubitemid 40586871)
10. Hill JC. The use of cyclosporine in high-risk keratoplasty. Am J Oph-thalmol. 1989;107:506-510. (Pubitemid 19136623)
11. Hill JC. Systemic cyclosporine in high-risk keratoplasty. Short-versus long-term therapy. Ophthalmology. 1994;101:128-133. (Pubitemid 24044153)
12. Inoue K, Amano S, Kimura C, et al. Long-term outcome of topical cyclosporine treatment following penetrating keratoplasty [in Japanese]. Nippon Ganka Gakkai Zasshi. 1999;103:306-310. (Pubitemid 29220030)
13. Miller K, Huber C, Niederwieser D, et al. Successful engraftment of high-risk corneal allografts with short-term immunosuppression with cyclosporine. Transplantation. 1988;45:651-653. (Pubitemid 18086579)
14. Pescovitz MD, Barbeito R; Simulect US01 Study Group. Two-hour postdose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant. 2002;16:378-382.
15. Robert PY, Delbosc B, Preux PM, et al. Treatment with cyclosporin A, with low doses, in high-risk penetrating keratoplasties. A bi-centric study of 90 cases [in French]. J Fr Ophtalmol. 1997;20:507-514. (Pubitemid 27395850)
16. Rossa V, Sundmacher R, Heering P. Preventive systemic cyclosporin A in risk keratoplasty [in German]. Klin Monbl Augenheilkd. 1990;197: 466-469.
17. Rumelt S, Bersudsky V, Blum-Hareuveni T, et al. Systemic cyclosporin A in high failure risk, repeated corneal transplantation. Br J Opthalmol. 2002;86:988-992. (Pubitemid 34953611)
18. Shimazaki J, Den S, Omoto M, et al. Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Opthalmol. 2011;152:33-39. e31.
19. Kobayashi C, Kanai A, Nakajima A, et al. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. Transpl Proc. 1989;21:3156-3158. (Pubitemid 19124697)
20. Joseph A, Raj D, Shanmuganathan V, et al. Tacrolimus immunosuppres-sion in high-risk corneal grafts. Br J Opthalmol. 2007;91:51-55. (Pubitemid 46094009)
21. Liang L, Sheha H, Tseng SC. Long-term outcomes of keratolimbal allo-graft for total limbal stem cell deficiency using combined immunosuppres-sive agents and correction of ocular surface deficits. Arch Ophthalmol. 2009;127:1428-1434.
22. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology. 2001;108: 1838-1844. (Pubitemid 32905941)
23. Ciancio G, Burke GW, Jorge D, et al. Immunosuppressive treatment options in renal transplantation. Minerva Urol Nefrol. 2005;57:141-149. (Pubitemid 43942551)
24. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppres-sion in renal transplantation: meta-analysis of randomised trials. BMJ. 1999;318:1104-1107. (Pubitemid 29192148)
25. Krämer BK, Montagnino G, Del Castillo D, et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant. 2005;20: 968-973. (Pubitemid 40704035)
26. McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analy-sis. Am J Transpl. 2006;6:1578-1585. (Pubitemid 43945797)
27. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclo-sporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005; 331:810.
28. Daniell MD, Dart JK, Lightman S. Use of cyclosporin in the treatment of steroid resistant post-keratoplasty atopic sclerokeratitis. Br J Opthalmol. 2001;85:91-92. (Pubitemid 32060203)
29. Lyons CJ, Dart JK, Aclimandos WA, et al. Sclerokeratitis after kerato-plasty in atopy. Ophthalmology. 1990;97:729-733.
30. Tomita M, Shimmura S, Tsubota K, et al. Postkeratoplasty atopic scle-rokeratitis in keratoconus patients. Ophthalmology. 2008;115:851-856. (Pubitemid 351602294)